Non-classic adrenal hyperplasia, laboratory characteristics and treatment response. Cohort study
PDF (Español (España))
HTML (Español (España))


Adrenal Hyperplasia, Congenital
Adrenocorticotropic Hormone

How to Cite

Abreu Lomba , A., González Bermúdez, C., Salazar, L., Bolena Muriel , A., Gómez, M., & Hernández-Carrillo, M. (2021). Non-classic adrenal hyperplasia, laboratory characteristics and treatment response. Cohort study. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 7(4), 236–242.


Objective: To compare the laboratory characteristics and response to treatment in a cohort of patients with non-classical congenital adrenal hyperplasia followed during 12 months.

Methods: A study was conducted in a cohort of 38 patients with non-classical adrenal hyperplasia from January 2006 to December 2016. The characteristics of the study population and the response of 17-hydroxyprogesterone (17-OH progesterone), testosterone, and dehydroepiandrosterone sulfate (DHEA-S) are reported 6 and 12 months after treatment with dexamethasone, and ethinyl estradiol/cyproterone acetate. A multiple linear regression analysis was performed in order to explain the change of the outcome variables (17-OH progesterone, testosterone, and DHEA-S), adjusted according to body mass index (BMI) and age as covariates.

Results: The average age of the participants was 25 years and average BMI was 28.3 kg/m2. The most prevalent clinical features were acne (52.6%) and oligomenorrhea (55%). Hirsutism occurred to some degree in all cases (31.6% moderate and 39.5% severe, according to the Ferriman-Gallwey scale). The change in the levels of each hormone reflected a significant decrease in the median and interquartile range levels of 17-OH progesterone, testosterone and DHEA-S, at 6 and 12 months (p <0.05). In the multiple linear regression, the levels of testosterone showed variation according to BMI (p = 0.04). In this study, pharmacological therapy with dexamethasone was applied at different doses and all patients were given contraceptives, with adequate clinical and paraclinical response at 1 year of follow-up.

Conclusion: This study suggests that the combination of cyproterone plus ethinyl estradiol with variable doses of dexamethasone decreases the androgenic profile in patients with non-classic adrenal hyperplasia followed over a 1-year period.
PDF (Español (España))
HTML (Español (España))


Bidet M, Bellanné-Chantelot C, Galand-Portier M-B, Tardy V, Billaud L, Laborde K, et al Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab. 2009;94(5):1570-8.

Latorre S, Garzón C, Manosalva G, Merchán S, Jacomussi L, Maldonado S. Hiperplasia adrenal congénita por déficit de 21 hidroxilasa: un reto diagnóstico y terapéutico. Repert Med Cir. 2016;25(2):79-88.

Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab. 2008;93(2):527-33.

Parajes S, Loidi L, Reisch N, Dhir V, Rose IT, Hampel R, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: four mutations associated with non classic and three mutations causing classic 11{beta}-hydroxylase deficiency. J Clin Endocrinol Metab. 2010;95(2):779-88.

Reisch N, Arlt W, Krone N. Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res Paediatr. 2011;76(2):73-85.

El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet. 2017;390(10108):2194-2210.

Lin-Su K, Nimkarn S, New MI. Congenital adrenal hyperplasia in adolescents: diagnosis and management. Ann N Y Acad Sci. 2008;1135:95-8.

Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord. 2009;10(1):77-82.

New MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2006;91(11):4205-14.

Siegel SF, Finegold DN, Urban MD, McVie R, Lee PA. Premature pubarche: etiological heterogeneity. J Clin Endocrinol Metab. 1992;74(2):239-47.

Merino P, Bachega T, Céspedes P, Trejo L, Billerbeck AE, Codner E. Utilidad del estudio molecular de CYP21A2 en el manejo prenatal de hiperplasia suprarrenal congénita: detección de dos nuevas mutaciones en Chile. Rev Méd Chile. 2007;135(11):1450-5.

Alonso M, Ezquieta B. Hiperplasia suprarrenal congénita no clásica o tardía. Rev Esp Endocrinol Pediatr. 2012; 3(Suppl):61-73.

Moran C, Azziz R, Carmina E, Dewailly D, Fruzzetti F, Ibanez L, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol. 2000;183(6):1468-74.

Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012;97(12):4429-38.

Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Pediatr Clin North Am. 2011;58(5):1281-300.

Loriaux DL. An approach to the patient with hirsutism. J Clin Endocrinol Metab. 2012;97(9):2957-68.

Labarta JI, Bello E, Ruiz-Echarri M, Rueda C, Martul P, Mayayo E, et al. Estado en la edad adulta y propuesta de optimización terapéutica de la hiperplasia suprarrenal congénita. An Pediatr 2003;58(Supl 2):12-34.

Carvajal Martínez F, Montesino Estévez T, Espinosa Reyes T, Navarrete Cabrera J, Pérez Gesén C. Forma no clásica de hiperplasia adrenal congénita en la niñez y adolescencia. Rev Cubana Endocrinol. 2010;21(1): 62-73.

Sava?-Erdeve ?, Çetinkaya S, Abal? ZY, Poyrazo?lu ?, Ba? F, Berbero?lu M, et al. Clinical, biochemical and genetic features with nonclassical 21-hydroxylase deficiency and final height. J Pediatr Endocrinol Metab. 2017;30(7):759-766.

Speiser PW. Congenital Adrenal Hyperplasia. F1000Res. 2015;4(F1000 Faculty Rev):601.

Carmina E, Dewailly D, Escobar-Morreale HF, Kelestimur F, Moran C, Oberfield S, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update. 2017;23(5):580-599.

Grandone A, Marzuillo P, Luongo C, Toraldo R, Mariani M, Miraglia Del Giudice E, et al. Basal levels of 17-hydroxyprogesterone can distinguish children with isolated precocious pubarche. Pediatr Res. 2018;84(4):533-6.

Spritzer P, Billaud L, Thalabard JC, Birman P, Mowszowicz I, Raux-Demay MC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990;70(3):642-6.

Livadas S, Dracopoulou M, Dastamani A, Sertedaki A, Maniati-Christidi M, Magiakou AM, et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol (Oxf). 2015;82(4):543-9.

Young J, Tardy V, de la Perrière AB, Bachelot A, Morel Y; French Society of Endocrinology. Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. Ann Endocrinol (Paris). 2010;71(1):14-8.

Falhammar H, Nordenström A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine. 2015;50(1):32-50.

Frank-Raue K, Junga G, Raue F, Vecsei P, Ziegler R. Therapie des Hirsutismus bei Frauen mit adrenalen Enzymdefekten der Steroidhormonbiosynthese: Vergleich von Dexamethason mit Cyproteronacetat. Klin Wochenschr. 1990;68(12):597-601.

Demers LM. Biochemistry and laboratory measurement of androgens in women. En: Redmond GP (editor). Androgenic disorders. Nueva York: Raven Press; 1995. p. 21-34.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.




Download data is not yet available.